NOS3 tagSNPs does not modify the chronic kidney disease progression in autosomal dominant polycystic kidney disease

Nephrology

Volumn 19, Issue 9, 2014, Pages 537-541

  Ramanathan, Gnanasambandan ^a   Periyasamy, Soundararajan ^a   Lakkakula, Bhaskar Vks ^a,b  

^a SRI RAMACHANDRA UNIVERSITY   (India)

^b Sickle Cell Institute Chhattisgarh   (India)

Author keywords

chronic kidney disease; genetics; hypertension

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, HUMAN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COMPUTER PROGRAM; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; ELECTROPHORESIS; FAMILY HISTORY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE; HUMAN; HYPERTENSION; INTRON; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STRATIFICATION; UNIVARIATE ANALYSIS; AGED; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; COMPLICATION; ENZYMOLOGY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PHENOTYPE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENAL INSUFFICIENCY, CHRONIC; RISK; RISK FACTOR; VARIABLE NUMBER OF TANDEM REPEAT;

ADULT; AGED; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INTRONS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MINISATELLITE REPEATS; NITRIC OXIDE SYNTHASE TYPE III; ODDS RATIO; PHENOTYPE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; POLYMORPHISM, SINGLE NUCLEOTIDE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84906679094     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12278     Document Type: Article

References (31)

1. Barua M, Cil O, Paterson AD, et al. Family history of renal disease severity predicts the mutated gene in ADPKD. J. Am. Soc. Nephrol. 2009; 20: 1833-1838.
2. Pei Y,. Diagnostic approach in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2006; 1: 1108-1114.
3. Rossetti S, Burton S, Strmecki L, et al. The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J. Am. Soc. Nephrol. 2002; 13: 1230-1237.
4. Schrier RW, Johnson AM, McFann K, Chapman AB,. The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int. 2003; 64: 1792-1799.
5. Pereira AC, Sposito AC, Mota GF, et al. Endothelial nitric oxide synthase gene variant modulates the relationship between serum cholesterol levels and blood pressure in the general population: New evidence for a direct effect of lipids in arterial blood pressure. Atherosclerosis 2006; 184: 193-200.
6. Devuyst O, Persu A, Vo-Cong MT,. Autosomal dominant polycystic kidney disease: Modifier genes and endothelial dysfunction. Nephrol. Dial. Transplant. 2003; 18: 2211-2215.
7. Wang D, Iversen J, Strandgaard S,. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2000; 11: 1371-1376.
8. Persu A, Stoenoiu MS, Messiaen T, et al. Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum. Mol. Genet. 2002; 11: 229-241.
9. Walker D, Consugar M, Slezak J, et al. The ENOS polymorphism is not associated with severity of renal disease in polycystic kidney disease 1. Am. J. Kidney Dis. 2003; 41: 90-94.
10. Dasar N, Ghaderian SM, Azargashb E,. Human evaluation of the Glu298Asp polymorphism in NOS3 gene and its relationship with onset age of ESRD in Iranian patients suffering from ADPKD. Int. J. Mol. Cell. Med. 2012; 1: 105-112.
11. Bihoreau MT, Megel N, Brown JH, et al. Characterization of a major modifier locus for polycystic kidney disease (Modpkdr1) in the Han:SPRD(cy/+) rat in a region conserved with a mouse modifier locus for Alport syndrome. Hum. Mol. Genet. 2002; 11: 2165-2173.
12. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM,. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994; 343: 824-827.
13. NKF. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002; 39: S1-266.
14. Sambrook J, Russell DW,. Molecular Cloning: A Laboratory Manual, 3rd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2001.
15. Barrett JC, Fry B, Maller J, Daly MJ,. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
16. Didenko VV,. DNA probes using fluorescence resonance energy transfer (FRET): Designs and applications. Biotechniques 2001; 31: 1106-1116, 18, 20-1.
17. Nath SD, He X, Voruganti VS, et al. The 27-bp repeat polymorphism in intron 4 (27 bp-VNTR) of endothelial nitric oxide synthase (eNOS) gene is associated with albumin to creatinine ratio in Mexican Americans. Mol. Cell. Biochem. 2009; 331: 201-205.
18. Torres VE, Grantham JJ, Chapman AB, et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2011; 6: 640-647.
19. Kazancioglu R, Ecder T, Altintepe L, et al. Demographic and clinical characteristics of patients with autosomal dominant polycystic kidney disease: A multicenter experience. Nephron Clin. Pract. 2011; 117: c270-275.
20. Ahmed ER, Tashkandi MA, Nahrir S, Maulana A,. Retrospective analysis of factors affecting the progression of chronic renal failure in adult polycystic kidney disease. Saudi J. Kidney Dis. Transpl. 2006; 17: 511-515.
21. Idrizi A, Barbullushi M, Strakosha A, et al. [The relation of hypertension, renal function and cardiovascular events in autosomal dominant polycystic kidney disease]. G. Ital. Nefrol. 2007; 24: 595-599.
22. Orskov B, Romming Sorensen V, Feldt-Rasmussen B, Strandgaard S,. Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark. Clin. J. Am. Soc. Nephrol. 2010; 5: 2034-2039.
23. Patch C, Charlton J, Roderick PJ, Gulliford MC,. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: A population-based study. Am. J. Kidney Dis. 2011; 57: 856-862.
24. Yoshida I, Bengal R, Torres VE,. Gender-dependent effect of L-NAME on polycystic kidney disease in Han:SPRD rats. Am. J. Kidney Dis. 2000; 35: 930-936.
25. Reiterova J, Merta M, Tesar V, Stekrova J,. Endothelial nitric oxide synthase affects the progression of autosomal dominant polycystic kidney disease. Kidney Blood Press. Res. 2002; 25: 87-90.
26. Nakayama M, Yasue H, Yoshimura M, et al. T(-786) - > C mutation in the 5-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am. J. Cardiol. 2000; 86: 628-634.
27. Lamnissou K, Zirogiannis P, Trygonis S, et al. Evidence for association of endothelial cell nitric oxide synthase gene polymorphism with earlier progression to end-stage renal disease in a cohort of Hellens from Greece and Cyprus. Genet. Test. 2004; 8: 319-324.
28. Noiri E, Satoh H, Taguchi J, et al. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 2002; 40: 535-540.
29. Stefanakis N, Ziroyiannis P, Trygonis S, Lamnissou K,. Modifier effect of the Glu298Asp polymorphism of endothelial nitric oxide synthase gene in autosomal-dominant polycystic kidney disease. Nephron Clin. Pract. 2008; 110: c101-106.
30. Reiterova J, Miroslav M, Stekrova J, et al. The influence of G-protein beta3-subunit gene and endothelial nitric oxide synthase gene in exon 7 polymorphisms on progression of autosomal dominant polycystic kidney disease. Ren. Fail. 2004; 26: 119-125.
31. Tazon-Vega B, Vilardell M, Perez-Oller L, et al. Study of candidate genes affecting the progression of renal disease in autosomal dominant polycystic kidney disease type 1. Nephrol. Dial. Transplant. 2007; 22: 1567-1577.